219 related articles for article (PubMed ID: 31305009)
41. Genomics and drug profiling of fatal TCF3-HLF-positive acute lymphoblastic leukemia identifies recurrent mutation patterns and therapeutic options.
Fischer U; Forster M; Rinaldi A; Risch T; Sungalee S; Warnatz HJ; Bornhauser B; Gombert M; Kratsch C; Stütz AM; Sultan M; Tchinda J; Worth CL; Amstislavskiy V; Badarinarayan N; Baruchel A; Bartram T; Basso G; Canpolat C; Cario G; Cavé H; Dakaj D; Delorenzi M; Dobay MP; Eckert C; Ellinghaus E; Eugster S; Frismantas V; Ginzel S; Haas OA; Heidenreich O; Hemmrich-Stanisak G; Hezaveh K; Höll JI; Hornhardt S; Husemann P; Kachroo P; Kratz CP; Te Kronnie G; Marovca B; Niggli F; McHardy AC; Moorman AV; Panzer-Grümayer R; Petersen BS; Raeder B; Ralser M; Rosenstiel P; Schäfer D; Schrappe M; Schreiber S; Schütte M; Stade B; Thiele R; von der Weid N; Vora A; Zaliova M; Zhang L; Zichner T; Zimmermann M; Lehrach H; Borkhardt A; Bourquin JP; Franke A; Korbel JO; Stanulla M; Yaspo ML
Nat Genet; 2015 Sep; 47(9):1020-1029. PubMed ID: 26214592
[TBL] [Abstract][Full Text] [Related]
42. Correlation between permeability-related glycoprotein expression and susceptibilty to oxygen radicals in vincristine-resistant hematologic cell lines.
Hirose M; Hamano S; Hosoi E; Kuroda Y
Cancer Lett; 1997 Dec; 120(2):179-84. PubMed ID: 9461035
[TBL] [Abstract][Full Text] [Related]
43. Expression of identical E2A/PBX1 fusion transcripts occurs in both pre-B and early pre-B immunological subtypes of childhood acute lymphoblastic leukemia.
Izraeli S; Henn T; Strobl H; Ludwig WD; Kovar H; Haas OA; Harbott J; Bartram CR; Gadner H; Lion T
Leukemia; 1993 Dec; 7(12):2054-6. PubMed ID: 8255105
[TBL] [Abstract][Full Text] [Related]
44. Induction of apoptosis and bcl-2 expression in acute lymphoblastic leukaemia and non-Hodgkin's lymphoma in children.
Pituch-Noworolska A; Hajto B; Balwierz W; Klus K
Haematologia (Budap); 2001; 31(3):191-207. PubMed ID: 11855781
[TBL] [Abstract][Full Text] [Related]
45. Predictability of the t(1;19)(q23;p13) from surface antigen phenotype: implications for screening cases of childhood acute lymphoblastic leukemia for molecular analysis: a Pediatric Oncology Group study.
Borowitz MJ; Hunger SP; Carroll AJ; Shuster JJ; Pullen DJ; Steuber CP; Cleary ML
Blood; 1993 Aug; 82(4):1086-91. PubMed ID: 8353275
[TBL] [Abstract][Full Text] [Related]
46. Treatment of high-risk acute lymphoblastic leukemia in children using the AL851 and ALHR88 protocols: a report from the Kyushu-Yamaguchi Children's Cancer Study Group in Japan.
Matsuzaki A; Ishii E; Okamura J; Eguchi H; Yoshida N; Yanai F; Inoue T; Miyake K; Ishihara T; Tsuboi C
Med Pediatr Oncol; 1996 Jan; 26(1):10-9. PubMed ID: 7494507
[TBL] [Abstract][Full Text] [Related]
47. A novel PAX5 rearrangement in TCF3-PBX1 acute lymphoblastic leukemia: a case report.
Barbosa TC; Lopes BA; Blunck CB; Mansur MB; Deyl AVS; Emerenciano M; Pombo-de-Oliveira MS
BMC Med Genomics; 2018 Dec; 11(1):122. PubMed ID: 30563523
[TBL] [Abstract][Full Text] [Related]
48. Expression levels of TEL, AML1, and the fusion products TEL-AML1 and AML1-TEL versus drug sensitivity and clinical outcome in t(12;21)-positive pediatric acute lymphoblastic leukemia.
Stams WA; den Boer ML; Beverloo HB; Meijerink JP; van Wering ER; Janka-Schaub GE; Pieters R
Clin Cancer Res; 2005 Apr; 11(8):2974-80. PubMed ID: 15837750
[TBL] [Abstract][Full Text] [Related]
49. Efficacy and safety of induction chemotherapy with daunorubicin or idarubicin in the treatment of an adult with acute lymphoblastic leukemia.
Zhang Q; Zhang CH; Wang ZD; Wang D
Tumori; 2022 Apr; 108(2):182-188. PubMed ID: 34296648
[TBL] [Abstract][Full Text] [Related]
50. Personalized medicine in adult acute lymphoblastic leukemia.
Hoelzer D
Haematologica; 2015 Jul; 100(7):855-8. PubMed ID: 26130512
[No Abstract] [Full Text] [Related]
51. P-glycoprotein, lung resistance-related protein and multidrug resistance-associated protein in de novo adult acute lymphoblastic leukaemia.
Damiani D; Michelutti A; Michieli M; Masolini P; Stocchi R; Geromin A; Ermacora A; Russo D; Fanin R; Baccarani M
Br J Haematol; 2002 Mar; 116(3):519-27. PubMed ID: 11849207
[TBL] [Abstract][Full Text] [Related]
52. Addition of etoposide to initial therapy of adult acute lymphoblastic leukemia: a combined clinical and laboratory study.
Kaufmann SH; Karp JE; Burke PJ; Gore SD
Leuk Lymphoma; 1996 Sep; 23(1-2):71-83. PubMed ID: 9021688
[TBL] [Abstract][Full Text] [Related]
53. STI571 combined with vincristine greatly suppressed the tumor formation of multidrug-resistant K562 cells in a human-nude mice xenograft model.
Gao L; Chen L; Fei XH; Qiu HY; Zhou H; Wang JM
Chin Med J (Engl); 2006 Jun; 119(11):911-8. PubMed ID: 16780770
[TBL] [Abstract][Full Text] [Related]
54. Cytotoxic effects of vitamin A in combination with vincristine, daunorubicin and 6-thioguanine upon cells from lymphoblastic leukemic patients.
Pieters R; Huismans DR; Loonen AH; Hählen K; Veerman AJ
Jpn J Cancer Res; 1991 Sep; 82(9):1051-5. PubMed ID: 1938600
[TBL] [Abstract][Full Text] [Related]
55. Poor outcome of adult acute lymphoblastic leukemia patients carrying the (1;19)(q23;p13) translocation.
Piccaluga PP; Malagola M; Rondoni M; Ottaviani E; Testoni N; Laterza C; Visani G; Pileri SA; Martinelli G; Baccarani M
Leuk Lymphoma; 2006 Mar; 47(3):469-72. PubMed ID: 16396770
[TBL] [Abstract][Full Text] [Related]
56. Pyramidatine (Z88) Sensitizes Vincristine-Resistant Human Oral Cancer (KB/VCR) Cells to Chemotherapeutic Agents by Inhibition of P-glycoprotein.
Liu Z; Zhu H; Qu S; Tang L; Cao L; Yu W; Yang X; Jiang S; Zhu D; Tan C; Yu L
Anticancer Agents Med Chem; 2018; 18(2):286-294. PubMed ID: 28782465
[TBL] [Abstract][Full Text] [Related]
57. E2A/HLF fusion cDNAs and the use of RT-PCR for the detection of minimal residual disease in t(17;19)(q22;p13) acute lymphoblastic leukemia.
Devaraj PE; Foroni L; Sekhar M; Butler T; Wright F; Mehta A; Samson D; Prentice HG; Hoffbrand AV; Secker-Walker LM
Leukemia; 1994 Jul; 8(7):1131-8. PubMed ID: 7518549
[TBL] [Abstract][Full Text] [Related]
58. Effectiveness of rubidomycin in induction therapy with vincristine, prednisone, and L-asparaginase for standard risk childhood acute lymphocytic leukemia: results of a Dutch phase III study (ALL V). A report on behalf of the Dutch Childhood Leukemia Study Group (DCLSG).
van der Does-van den Berg A; van Wering ER; Suciu S; Solbu G; van 't Veer MB; Rammeloo JA; de Koning J; van Zanen GE
Am J Pediatr Hematol Oncol; 1989; 11(2):125-33. PubMed ID: 2665546
[TBL] [Abstract][Full Text] [Related]
59. Myeloid antigen co-expression in childhood acute lymphoblastic leukaemia: relationship with in vitro drug resistance.
Den Boer ML; Kapaun P; Pieters R; Kazemier KM; Janka-Schaub GE; Veerman AJ
Br J Haematol; 1999 Jun; 105(4):876-82. PubMed ID: 10554796
[TBL] [Abstract][Full Text] [Related]
60. Childhood acute lymphoblastic leukemia with the MLL-ENL fusion and t(11;19)(q23;p13.3) translocation.
Rubnitz JE; Camitta BM; Mahmoud H; Raimondi SC; Carroll AJ; Borowitz MJ; Shuster JJ; Link MP; Pullen DJ; Downing JR; Behm FG; Pui CH
J Clin Oncol; 1999 Jan; 17(1):191-6. PubMed ID: 10458233
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
